Investors & Media

News

ALL RELEASES

Summary Toggle Cyclacel’s CYC065 CDK Inhibitor Demonstrates Synergy With Venetoclax By Dual Targeting Of Chronic Lymphocytic Leukemia

04/17/18

Suppression of both BCl-2 and Mcl-1 anti-apoptotic proteins is a novel strategy in CLL BERKELEY HEIGHTS, N.J. , April 17, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that

Read more

PDF Version
Summary Toggle Cyclacel Announces Presentation of Phase 1 Clinical Data for CDK Inhibitor CYC065 at AACR 2018 Annual Meeting

04/16/18

Durable Mcl-1 suppression of at least 24 hours after a single dose of CYC065 BERKELEY HEIGHTS, N.J. , April 16, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target the

Read more

PDF Version
Summary Toggle Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results

03/28/18

Conference Call Scheduled March 28, 2018 at 4:30 p.m. EDT BERKELEY HEIGHTS, N.J. , March 28, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company") a biopharmaceutical company developing oral therapies that target the various phases of

Read more

PDF Version
Summary Toggle Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2017 Financial Results

03/21/18

BERKELEY HEIGHTS, N.J. , March 21, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other
Read more

PDF Version
Summary Toggle Phase 1 Clinical Data With Cyclacel’s CYC065 CDK Inhibitor Have Been Selected for Oral Presentation at AACR 2018 Annual Meeting

03/15/18

Further abstract selected with preclinical data of CYC065 and venetoclax combination in CLL BERKELEY HEIGHTS, N.J. , March 15, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies
Read more

PDF Version
Summary Toggle Cyclacel Pharmaceuticals to Present at the 30th Annual ROTH Conference

03/06/18

BERKELEY HEIGHTS, N.J. , March 06, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a clinical-stage biopharmaceutical company using cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted
Read more

PDF Version
Summary Toggle Cyclacel Announces Notice of Grant of New European Patent Covering Sapacitabine Pharmaceutical Formulations

02/21/18

Granted Patent Broadens Exclusivity of Sapacitabine BERKELEY HEIGHTS, N.J. , Feb. 21, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target the various phases of cell
Read more

PDF Version
Summary Toggle Cyclacel Pharmaceuticals to Present at the 2018 BIO CEO & Investor Conference

02/06/18

BERKELEY HEIGHTS, N.J., Feb. 06, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a clinical-stage biopharmaceutical company using cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted
Read more
Summary Toggle Cyclacel Pharmaceuticals to Present at the Noble Capital Markets Investor Conference

01/24/18

BERKELEY HEIGHTS, N.J., Jan. 24, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a clinical-stage biopharmaceutical company using cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted
Read more

Cyclacel Pharmaceuticals to Present at the Noble Capital Markets Investor Conference 18.9 KB
Summary Toggle Cyclacel Reviews 2017 Achievements and Announces Key Business Objectives for 2018

01/09/18

Company to Present at the Biotech ShowcaseTM 2018 Conference
Read more
Summary Toggle Cyclacel Announces Presentation of Results From Phase 3 Seamless Study at Ash Annual Meeting

12/12/17

BERKELEY HEIGHTS, N.J., Dec. 12, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) "Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target various phases of cell cycle control for the treatment of cancer and other serious
Read more

Cyclacel Announces Presentation of Results From Phase 3 Seamless Study at Ash Annual Meeting 24.7 KB
Summary Toggle Cyclacel Pharmaceuticals Reports Third Quarter 2017 Financial Results

11/09/17

— Conference Call Scheduled November 9, 2017 at 4:30 p.m. ET —
Read more

Cyclacel Pharmaceuticals Reports Third Quarter 2017 Financial Results 46.1 KB
Summary Toggle Cyclacel Pharmaceuticals to Release Third Quarter 2017 Financial Results

11/02/17

BERKELEY HEIGHTS, N.J., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a clinical-stage biopharmaceutical company using cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted
Read more

Cyclacel Pharmaceuticals to Release Third Quarter 2017 Financial Results 18 KB
Summary Toggle Cyclacel Pharmaceuticals Announces That Full Results From the Phase 3 Seamless Trial Have Been Selected for Oral Presentation at ASH 2017 Annual Meeting

11/01/17

BERKELEY HEIGHTS, N.J., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a clinical-stage biopharmaceutical company using cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted
Read more

Cyclacel Pharmaceuticals Announces That Full Results From the Phase 3 Seamless Trial Have Been Selected for Oral Presentation at ASH 2017 Annual Meeting 19.6 KB
Summary Toggle Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2017 Healthcare Conference

09/21/17

BERKELEY HEIGHTS, N.J., Sept. 21, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a clinical-stage biopharmaceutical company using cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted
Read more

Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2017 Healthcare Conference 17.9 KB
Summary Toggle Cyclacel Pharmaceuticals to Present at the 19th Annual Rodman & Renshaw Global Investment Conference

09/08/17

BERKELEY HEIGHTS, N.J., Sept. 08, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a clinical-stage biopharmaceutical company using cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted
Read more

Cyclacel Pharmaceuticals to Present at the 19th Annual Rodman & Renshaw Global Investment Conference 17.3 KB
Summary Toggle Cyclacel Pharmaceuticals Reports Second Quarter 2017 Financial Results

08/09/17

Conference Call Scheduled August 9, 2017 at 4:30 p.m. EDT

Read more

Cyclacel Pharmaceuticals Reports Second Quarter 2017 Financial Results 43 KB
Summary Toggle Cyclacel Announces Selection of Recommended Phase 2 Dose for CYC065 and Evidence of Durable Target Engagement and Mcl-1 Biomarker Suppression

08/07/17

Part 2 of study will focus on cyclin E amplified drug resistant solid tumors

Read more

Cyclacel Announces Selection of Recommended Phase 2 Dose for CYC065 and Evidence of Durable Target Engagement and Mcl-1 Biomarker Suppression 26.5 KB
Summary Toggle Cyclacel Pharmaceuticals to Release Second Quarter 2017 Financial Results

08/02/17

BERKELEY HEIGHTS, N.J., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other
Read more

Cyclacel Pharmaceuticals to Release Second Quarter 2017 Financial Results 17.7 KB
Summary Toggle Cyclacel Announces Closing of $15.2 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option

07/21/17

BERKELEY HEIGHTS, N.J., July 21, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (Cyclacel or the Company), a clinical-stage biopharmaceutical company using cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted medicines for
Read more

Cyclacel Announces Closing of $15.2 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option 20.5 KB

Share this on:
Delicious
Digg
Facebook
LinkedIn
Twitter